HCW Biologics Inc (HCWB)vsMerck & Company Inc (MRK)
HCWB
HCW Biologics Inc
$1.08
-6.09%
HEALTHCARE · Cap: $2.57M
MRK
Merck & Company Inc
$150.38
+3.93%
HEALTHCARE · Cap: $368.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1002370% more annual revenue ($67.38B vs $6.72M). MRK leads profitability with a 3.6% profit margin vs -83.1%. MRK earns a higher WallStSmart Score of 44/100 (D).
HCWB
Hold41
out of 100
Grade: D
MRK
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HCWB.
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$150.38
$65.72 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 1970.0% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -28.3% — below average capital efficiency
Trading at 8.9x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : HCWB
The strongest argument for HCWB centers on Price/Book, Revenue Growth. Revenue growth of 1970.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : HCWB
The primary concerns for HCWB are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
HCWB profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
HCWB carries more volatility with a beta of 2.27 — expect wider price swings.
HCWB is growing revenue faster at 1970.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (44/100 vs 41/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
HCW Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
HCW Biologics Inc is a forward-thinking biotechnology company focused on pioneering immunotherapies and vaccine technologies to tackle pressing health issues such as cancer and infectious diseases. Utilizing its proprietary platforms to amplify immune responses, HCW Biologics is actively expanding a promising pipeline of clinical candidates poised to make significant impacts in patient care. With a keen commitment to strategic partnerships and addressing urgent medical needs, the company aims to establish itself as a competitive force in the biotechnology landscape, presenting compelling investment opportunities that align with the evolving dynamics of the healthcare sector.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?